Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ISRCTN10699447) titled 'A study of Pasritamig (JNJ-78278343) in combination with JNJ-86974680 for treatment of prostate cancer' on Jan. 20.
Study Type: Interventional
Study Design:
Allocation: Non-randomized controlled trial
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Treatment
Primary Sponsor: Janssen-Cilag International NV
Condition:
Prostate cancer
Cancer
Intervention:
The study will be conducted in 2 Parts:
Part 1: Dose Finding, Participants will receive pasritamig in combination with JNJ-86974680 to determine the recommended phase 2 combination dose (RP2CD) regimen.
Part 2: Dose Expansio...